Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination

被引：0
|
作者：
Aydogdu, C. [1 ]
Paffenholz, P. [2 ,3 ]
Stelmach, R. [4 ]
Schlack, K. [5 ]
Roghmann, F. [6 ]
Handke, A. [6 ]
Mandal, S. [7 ]
Schnabel, M. [8 ]
Merseburger, A. [9 ]
Ivanyi, P. [10 ]
Tschaebitz, S. [4 ]
Darr, C. [11 ,12 ]
Gruenwald, V. [11 ,12 ]
Stief, C. G. [1 ]
Casuscelli, J. [1 ]
机构：
[1] Univ Hosp LMU Munich, Dept Urol, Munich, Germany
[2] Univ Cologne, Fac Med, Cologne, Germany
[3] Univ Hosp Cologne, Dept Urol & Urooncol & Robot Assisted & Reconstru, Cologne, Germany
[4] Heidelberg Univ Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Univ Hosp Munster, Dept Urol, Munster, Germany
[6] Univ Hosp Bochum, Dept Urol, Herne, Germany
[7] Univ Marburg, Dept Urol, Marburg, Germany
[8] Univ Regensburg, Dept Urol, Caritas St Josef Med Ctr, Regebsburg, Germany
[9] Univ Hosp Schleswig Holstein, Dept Urol, Lubeck, Germany
[10] Hannover Med Sch, Dept Hematol & Hemostasis & Oncol & Stem Cell Tra, Hannover, Germany
[11] Univ Duisburg Essen, Essen, Germany
[12] Univ Hosp Essen, Dept Urol, German Canc Consortium DKTK, Essen, Germany
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0837
引用
收藏
页码：S1858 / S1858
页数：1
相关论文
共 50 条
  • [1] Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination.
    Aydogdu, Can
    Paffenholz, Pia
    Stelmach, Ramona
    Schlack, Katrin
    Roghmann, Florian
    Handke, Analena
    Mandal, Subhajit
    Schnabel, Marco
    Merseburger, Axel
    Ivanyi, Philipp
    Zschaebitz, Stefanie
    Darr, Christopher
    Gruenwald, Viktor
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 436 - 436
  • [2] Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
    Chau, Vincent
    Bilusic, Marijo
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7321 - 7330
  • [4] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [5] In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
    不详
    ONKOUROLOGIYA, 2019, 15 (04): : 140 - 142
  • [6] Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma
    Dizman, Nazli
    Austin, Matthew
    Considine, Bryden
    Jessel, Shlomit
    Schoenfeld, David
    Merl, Man Yee
    Hurwitz, Michael
    Sznol, Mario
    Kluger, Harriet
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 221 - 229
  • [7] Advanced Renal Cell Cancer Combination of Pembrolizumab and Axitinib is the new Standard in the First Line Treatment
    Pickl, Susanne
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 707 - 707
  • [8] Pembrolizumab (KEYTRUDA®) in Combination with Axitinib (Inlyta®) for First-line Treatment of advanced Renal Cell Cancer Death Risk under Pembrolizumab Combination is almost halved Compared to Sunitinib
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (04) : 233 - 233
  • [9] Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
    Zhu, Jiaxin
    Zhang, Tiantian
    Wan, Ning
    Liang, Zhuoru
    Li, Jiahao
    Chen, Xudong
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (17) : 1237 - 1246
  • [10] KEYNOTE-426 Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
    Bedke, J.
    Stuehler, V.
    UROLOGE, 2020, 59 (07): : 841 - 842
12345